RecruitingGERDGastroesophageal RefluxGastroparesis
Compassionate Use of Domperidone for Refractory Gastroparesis
Eligible age
12–21 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this program is to allow the use of domperidone in children from 12 to 21 years of age with symptoms related to motility disorders and Gastroesophageal reflux disease (GERD) who have failed all the standard treatments for their condition.
Sponsor: Jose Cocjin
You may qualify if…
- ✓ 1. Male or female
- ✓ 2. Age 12 - 21
- ✓ 3. Symptoms or manifestations secondary to GERD (e.g., persistent esophagitis, heartburn, upper airway signs or symptoms or respiratory symptoms), gastrointestinal motility disorders such as nausea, vomiting, severe dyspepsia or severe chronic constipation that are refractory to standard therapy.
- ✓ 4. Patients must have a comprehensive evaluation to eliminate other causes of their symptoms.
- ✓ 5. Patient has signed informed consent for the administration of domperidone that informs the patient of potential adverse events including:
- ✓ increased prolactin levels
- ✓ extrapyramidal side effects
- ✓ breast changes
You may not qualify if…
- ✕ 1. History of, or current, arrhythmias including ventricular tachycardia, ventricular fibrillation and Torsade des Pointes. Patients with minor forms of ectopy (PACs) are not necessarily excluded.
- ✕ 2. Clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged Tc (QTc\> 450 milliseconds for males, QTc\>470 milliseconds for females).
- ✕ 3. Clinically significant electrolyte disorders.
- ✕ 4. Gastrointestinal hemorrhage or obstruction
- ✕ 5. Presence of a prolactinoma (prolactin-releasing pituitary tumor).
- ✕ 6. Pregnant or breast feeding female
- ✕ 7. Known allergy to domperidone
Where it's recruiting
Missouri
Kansas City
Source: ClinicalTrials.gov · NCT04699591 · last updated 2026-03-24